AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
IRVINE, Calif., Feb. 03, 2017 -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Vaseem Mahboob, Chief Financial Officer, is scheduled to present at Leerink Partners 6th Annual Global Healthcare Conference in New York, NY. The Leerink Conference will utilize a fireside chat format for the presentation.
| Event: | Leerink Partners 6th Annual Global Healthcare Conference |
| Date: | Wednesday, February 15, 2017 |
| Time: | 9:30 am ET |
An audio webcast of the Company’s presentation will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentation will be available for 90 days.
About Endologix, Inc.
Endologix, Inc., develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States. Additional information can be found on Endologix's website at www.endologix.com.
COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Zack Kubow (646) 536-7020 Nick Laudico (646) 536-7030
